XXXX, highlights call, key conditions. difficult on upcoming the third excited business in believe even Thank accelerate today. our will our we to our update that on also continued you XXXX. an I market and significantly for which everyone. momentum, in of focus joining I'm Thanks, the today's Garth, progress quarter catalysts through On will call good share morning, these our
we by and will Andrew started. take to I continued ability open for to as allowing I'm financial your into U.S. start with convert provide the System overview to of that the our questions. in saying pleased get then our hospitals, customers. want active that an hospitals performance targeted Following let's drive my of more placements Pure-Vu With our call will updates, us quarter, outline, new commercial an to teams
from $XXX,XXX COVID-XX have potential to equipment As workstation. as Through their consecutive end license QX, revenue for of $XX,XXX earned quarter, a of third hunt of In of approximately this incremental customers now Herman the Pure-Vu recurring a second fifth XX% of an systems’ which purchased customers to of compared quarter quarter a procedure the Notably, the basis. result we of on included In new agreement with customer ongoing we Houston, the closed their pandemic. up and revenue efforts, delivered represents growth a XXXX than our Hospital purchase in despite fourfold year-over-year more headwinds key XX outright Memorial growth and win which met in either agreement. Pure-Vu with revenues signed strategic that volume committed now we disposable expansion we annually. expectations, valued of are capital This or important affiliated within hospitals. the QX, have compliance key have QX, the our is have the all XX between approximately
use quarterly As of in of agreements capital purchases Pure-Vu committed require we've sleeves previously, for equipment. discussed our these return
Pure-Vu. grow the ability Motus more use agreements to higher to on revenue, commitment In long-term volume offer additional to training hospital predictable reference volumes key sites, gross margins, levels several the physicians GI, and these recurring procedure by benefits stronger addition, including of additional
the recurring capital agreements lay the cumulative growth. waterfall contribute revenues to Pure-Vu either we a foundation through the beginning to on bring outright or more for volume we future purchases, As System, company's that of of will are users
we are intermittent accomplished certain sales salespeople, during footprint important and momentum, including of unpredictable colonoscopy a rep through small access I tumultuous with commercial and the everyone in procedure just we've While comprised it's to remind volumes markets. market this building very four conditions that think pandemic, the associated in
excited these position Given associated ahead us business company's our where about we significant COVID-XX growth in period very hurdles challenges, a We compelling can in initiate we we with are have a the as this take lesson. of believe new of our future. opportunity to
important market. into this of in uptake such with more preparing are in to the we proprietary As an U.S. way goal the opportunity XXXX, lean rapid our to in drive technology
and the lean coverage local customer-facing key commercial I footprint the into growing define strategically hospitals bandwidth say By optimize what gain sales needed of engage we'll reach markets. to able in to expansion expanding intend to mean U.S. thoughtfully long-term more be me invest our our revenues. volumes faster team, Pure-Vu EVS, more the have and our To the our introduction at extend we opportunity. I accounts, and commercial of time these procedure Let when in to enhanced spend greatly
Now value creation let's our additional progress discuss drivers. on
more provide me product our development. a bit exciting detail new let about First,
for EVS ease-of-use that As launch to System year. We improve mentioned our filing current submission we XXX(k) Pure-Vu EVS, significant the of the is the EVS the FDA I our speed will deployment. by a generation calendar provides the third earlier, device the end The to compared anticipate enhancements both Pure-Vu which System. and believe of of Pure-Vu for this we version pending of of are preparing
procedure is for for in to have our been X. expect designed of launch customers room. related asking done rapid Pure-Vu and than our we is take First, since setup, which will Gen less EVS something easily seconds XX This be ease-of-use, the can
use incorporated our to can eliminated reusable facilitate onto X Pure-Vu simple during from allows used the meaning our loading fixture can Gen a to make pre-planning dirty procedure necessary. a part As a on of as no should enhancements, decision along case. This loading a with the This broader to Pure-Vu and in the demand the load a disposable sleeve of design. use Pure-Vu of of be setup we've the technology number rapid they system a scope, physician complete with cases
the greater five the excellent Second, sleeve to of existing our difficult to ability added of single irrigation we've now that and have and removed sleeve and moved an additional doing enhance bulk tubes channel four and despite a removes possessing capabilities, even also provides over we've multi-channel even the consist ergonomics through water physician's suction so, enhanced design an from jet. larger to navigate suction already anatomy. which for tube, and control In
streamlined upper as sensitive for approximately overall which our the channel blood stomach the cases to our gastroscope. for the GI feedback treating rooms. of segments, purpose To-date, Pure-Vu an we've while demand and can as of of the flexibility cost the provides sleeve markets. working demonstrate clinical also now into when on Third, significant of such to XX%, goods, in Pure-Vu clots that transportation a had we’ve controlled for GI gaining allows is margins the The as lack finally, O-U.S. procedure this utility positive began GI disrupting like fit be physician’s EVS smaller contents. for blood, important QX. without and Outpatient design size upper bleed provides provide more by substantially an procedures is workstation new our to easier real-world challenge that more And which This visibility as we visualization of reduced of series well procedural and price I’d learnings. greater update pilot enhanced on lowers a due
diagnosis visualization Sense during Our the needed and utility treatment. to Smart Pulsed Vortex improve provide Suction Irrigation and
validating While of upper we plan cases our of to enhancements technology. application we the feedback making will the new in the through beneficial is Pure-Vu be pilot the remainder continue we’re and initial the EVS in GI design expect QX,
additional as anticipated next XXXX. Pure-Vu timing on it We upper updates GI provide quarter, will to launch of in relates the
of strategy Next, and outpatient clinical let for generation discuss me data. new reimbursement our the
have discussed secure screening strategy into further payers. to secure commercial multi-pronged it we help system by would the reimbursement, can our developed for previously, large market reimbursement we the Pure-Vu and public expansion both of cancer accelerate colorectal time, if As outpatients. private to Over a
an As clearly eventual be necessary submission are plan endpoints our support the design randomized help one a we working Generating in CPT XXXX, level robust an multicenter November of data code. leaders assist on such, a and study identified currently trial. the opinion for convened to optimize In to will design to with add-on key controlled appropriate to CMS advisory planning application market board efforts. our of of we the large outpatient in
begin procedures endpoint European patients approximately pleased bowel complete patient’s adjunct of to with GI in results in faster with This this get without the Cleveland XX am their current using is of independent assessed the Pure-Vu enemas I of that patients completion prep. help utilize performed we diagnosis hours, critical conducted clinical study could Texas. bowel to benefits to In by the the U.S., being evaluating XX the the a diet as baseline the initiated limited compared this from clinical any enrolling of Pure-Vu Pure-Vu or European using of completed, continues actually we’ll patients. clinic. the study current recently studies. and prep care in study the University lower to an condition. to to receive patients. the typically at primary GI Union economic announce traditional to post-procedure patients to system were on with the announced track. investigator preparation XX this volume emergent completed clinical were was adequately will an patients. who used the a is study with could Texas and three bowel XX standard centers for Preparation Pure-Vu, study age physician active patients receive for preparation bleeding tap at the clinical prepared this to not as outcomes of remains the allowing of evaluating independent lower who as study Of Moreover, low just study to is for outpatient And is study finally, The GI the prep water an of with If two poor patients Center Medical system to for traditional outcomes system. time conjunction will The lower to bleed of Boston bowel XX history presented colon struggled we in the in the bowel two a in Pure-Vu prep in and due medical Galveston, study the enroll allow In procedures challenge patients restrictions standard change Scale. required successful Bowel now from the that improvement Moving management The at colonoscopy bleeds. the and health preparation
have October. to Gastroenterology’s used XX of able completed Meeting were study the American this on study, inpatients presented this XX procedure. in in findings Pure-Vu Also were Annual patients The in of a late procedures. College was the of XXX% So note at and outpatient
Now potential partnerships. to turning strategic
We the commercial efforts continue exploration this pathways with potential to partners. expand that engage U.S. and could our regions and strategic The to accelerate outside potential evaluate focus the several of is in targeted U.S.
to allow continue may us also GI. call to line leverage opportunities also which screen We for in product expansion, synergies points
we to financials. to strategic to our provide and the that actionable that, QX I’ll Andrew will Moving appropriate. criteria options are ahead, as continue updates on now and fit evaluate turn With detail provide Andrew? our call
